At least one KRAS mutation was detected in 6/18 (33.3%) paired plasma-derived cfDNA samples (1 patients with PDAC, 1 patient with IPMN, 1 patient with pancreatitis, and 3 controls), with mean FA values of 5.1% (+16.1) and 0.2% (+0.5) in the cases and controls, respectively. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.